Reported 13 days ago
AstraZeneca has announced a $445 million expansion of its manufacturing facility in Coppell, Texas, which will double the production of its hyperkalaemia treatment, Lokelma. The project includes a new 9,000 square foot building and upgrades to drug testing laboratories, to meet the growing demand for the treatment. This expansion is part of a larger commitment from AstraZeneca to enhance its manufacturing capabilities in the U.S., aiming for a total investment of $50 billion by 2030.
Source: YAHOO